Patents by Inventor William W. Freimuth

William W. Freimuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for use in treatment of patients with autoantibody positive disease
    Patent number: 9168286
    Abstract: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: October 27, 2015
    Assignee: Human Genome Sciences, Inc.
    Inventors: Marc Chevrier, William W. Freimuth, Zhenshao Zhong, Daniel Odenheimer
  • METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE
    Publication number: 20090148462
    Abstract: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.
    Type: Application
    Filed: June 6, 2008
    Publication date: June 11, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Marc Chevrier, William W. Freimuth, Zhenshao Zhong, Daniel Odenheimer, Melissa D. Perkins
  • METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE
    Publication number: 20090081231
    Abstract: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.
    Type: Application
    Filed: November 21, 2008
    Publication date: March 26, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Marc Chevrier, William W. Freimuth, Zhenshao Zhong, Daniel Odenheimer, Melissa D. Perkins
  • METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE
    Publication number: 20090081213
    Abstract: The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.
    Type: Application
    Filed: August 5, 2008
    Publication date: March 26, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: MARC CHEVRIER, William W. Freimuth, Zhenshao Zhong, Daniel Odenheimer, Melissa D. Perkins